News
About the PCSK9 Education and Research Forum
PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
Question of the Month
LDL cholesterol lowering and effects on plaque: what can we learn from INTENSITY-HIGH?Professor John Chapman
Download Now: New Slide Deck Programme
Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.
Find out more »
News from the Trials
Keep up to date with latest news and analyses from PCSK9 inhibitor trials.
- Inclisiran: Pooled analysis of ORION-9,10,11 reaffirms efficacy, short-term safety
- HUYGENS: How does PCSK9 inhibition with evolocumab impact plaque phenotype?
- ODYSSEY OUTCOMES: Lipoprotein(a) and diabetes risk
Trial Resources
For expert analysis and insights
Hot Topics
14th Closed Virtual Meeting of the Editorial Board of PCSK9 Forum
PCSK9 inhibition: The evolving treatment paradigm post-MI
Lowering of guideline-recommended LDL-C goals in the post-MI setting has implications for real-world practice. Here, PCSK9 Forum Editors discuss cases, using evidence from ODYSSEY OUTCOMES and FOURIER.
Prof Gregory Schwartz uses data from ODYSSEY OUTCOMES to support management strategies.
Prof Robert Giugliano discusses evidence from FOURIER in the context of managing FH patients.
From the Editors
Proof-of-concept: Gene-editing for PCSK9 inhibition
Prof. John Chapman, Pitié-Salpêtrière University Hospital, Sorbonne University, and National Institute for Health and Medical Research (INSERM), Paris, France.
Other related reports:
DA-VINCI: Need to do better with LDL cholesterol management in practice in Europe
Pooled analysis highlights the promise of inclisiran
Inclisiran: Update on efficacy, dosing regimen, safety and COVT trial
Very low lipoprotein(a) and very low LDL cholesterol – are they safe?
Latest Views
Meet our Editorial Board
View all our Editorial Board
Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie
Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research
Dr Michel FarnierClinician based at Point Medical, Dijon, France
Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit
Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology
